Clinical Trial Update: Study of Mocetinostat in Patients With Urothelial Carcinoma Having Inactivating Alterations of Specific Genes [Phase 2]

View source ↗

Summary

The document reports completion of a Phase 2 study evaluating Mocetinostat in patients with urothelial carcinoma who have inactivating alterations in select gen…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Urothelial Carcinoma

Drugs mentioned

• Mocetinostat (mocetinostat)

Snippet

Sponsor: Mirati Therapeutics Inc. | Conditions: Urothelial Carcinoma | Phase 2 | Status: COMPLETED